Financial Performance - Bristol Myers Squibb reported quarterly earnings of $1.80 per share, exceeding the Zacks Consensus Estimate of $1.51 per share, compared to a loss of $4.40 per share a year ago, representing an earnings surprise of 19.21% [1] - The company posted revenues of $11.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.38%, although this is a decrease from year-ago revenues of $11.87 billion [2] - Over the last four quarters, Bristol Myers has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.69 on revenues of $11.35 billion, and for the current fiscal year, it is $6.76 on revenues of $45.82 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution (PRINCETON, N.J., April 24, 2025) – Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squ ...

FILE PHOTO: The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023.Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs.The company now expects 2025 revenue to come in between $45.8 billion and $46.8 billion, up from a previous outlook of around $45.5 billion. Bristol Myers also expects full-year adjusted earnings of $6.70 to $7 per share, which c ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Core Viewpoint - Bristol Myers Squibb (BMY) is expected to report a significant increase in quarterly earnings per share, while revenues are projected to decline year-over-year [1]. Financial Projections - Analysts predict quarterly earnings of $1.54 per share, reflecting a 135% increase compared to the same period last year [1]. - Revenues are forecasted to be $10.74 billion, representing a year-over-year decrease of 9.5% [1]. - The consensus EPS estimate has been adjusted upward by 0.8% over the past 30 days, indicating a reassessment of initial projections by analysts [2]. Key Metrics Estimates - Net Sales for Recent LOE Products - Revlimid is estimated at $879.35 million, indicating a change of -47.3% from the prior-year quarter [5]. - Net Sales for In-Line Products - Opdivo is expected to reach $2.18 billion, reflecting a year-over-year change of +4.9% [5]. - Net Sales for Recent LOE Products - Abraxane is projected at $127.62 million, showing a change of -41.2% from the year-ago quarter [6]. - Net Sales for New Product Portfolio - Reblozyl is estimated at $483.40 million, indicating a change of +36.6% year-over-year [6]. - Net Sales for Recent LOE Products - Abraxane (U.S.) is expected to be $66.33 million, reflecting a year-over-year change of -54.3% [7]. - Net Sales for In-Line Products - Opdivo (U.S.) is projected at $1.19 billion, indicating a year-over-year change of +3.4% [7]. - Net Sales for In-Line Products - Pomalyst/Imnovid (U.S.) is expected to reach $582.15 million, reflecting a change of -2.5% from the prior-year quarter [8]. - Net Sales for Recent LOE Products - Revlimid (U.S.) is estimated at $706.32 million, indicating a change of -51.4% from the prior-year quarter [9]. - Net Sales for New Product Portfolio - Reblozyl (U.S.) is projected at $392.41 million, reflecting a change of +33.9% from the prior-year quarter [10]. Market Performance - Over the past month, Bristol Myers shares have recorded returns of -18.5%, compared to the Zacks S&P 500 composite's -6.9% change [10]. - Based on its Zacks Rank 3 (Hold), BMY is expected to perform in line with the overall market in the upcoming period [10].

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2025 results on April 24, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $10.74 billion and $1.54 per share, respectively.Earnings estimate for 2025 has increased to $6.78 from $6.75 per share over the past 30 days, while that for 2026 has decreased to $6.06 from $6.08. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchBMY’s ...

Gilead Sciences, Inc. (GILD) and Bristol Myers Squibb (BMY) are leading biotechnology companies with broad and diverse portfolios and a global footprint.Gilead Sciences is a pioneer in developing treatments for human immunodeficiency virus (HIV). The company’s wide portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases.On the other hand, Bristo Myers is focused on discovering, developing and delivering transformational drugs for oncology, hematology, immunology, c ...

Bristol Myers Squibb (BMY) suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten).The phase III study was evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM).The dual-primary endpoints for the trial were to examine changes from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumpt ...

Group 1: Stock Performance - Bristol Myers Squibb (BMY) stock closed at $53.78, showing a +1.34% change from the previous day's closing price, but lagged behind the S&P 500's daily gain of 9.52% [1] - The stock has decreased by 13.72% over the past month, which is worse than the Medical sector's loss of 14.16% and the S&P 500's loss of 13.47% [1] Group 2: Upcoming Earnings - The earnings report for Bristol Myers Squibb is anticipated on April 24, 2025, with expected earnings of $1.55 per share, reflecting a year-over-year growth of 135.23% [2] - Revenue is projected to be $10.69 billion, indicating a 9.94% decline from the same quarter last year [2] Group 3: Full Year Estimates - For the full year, earnings are estimated at $6.75 per share, representing a +486.96% change from the previous year, while revenue is projected at $45.59 billion, showing a -5.6% change [3] Group 4: Analyst Estimates - Recent changes in analyst estimates for Bristol Myers Squibb suggest a positive outlook on the company's business operations and profit generation capabilities [4] - The Zacks Rank system, which reflects these estimate changes, indicates a current rank of 3 (Hold) for Bristol Myers Squibb [6] Group 5: Valuation Metrics - Bristol Myers Squibb is currently trading at a Forward P/E ratio of 7.86, which is below the industry average Forward P/E of 15.86 [7] - The company has a PEG ratio of 1.97, compared to the industry average PEG ratio of 1.31, indicating a relatively higher valuation based on anticipated earnings growth [8] Group 6: Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [8][9]

Core Viewpoint - Bristol Myers Squibb (BMY) has received FDA approval for the label expansion of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in adult and pediatric patients aged 12 years and older [1][2] Company Developments - The latest FDA approval converts the previous accelerated approval for Opdivo monotherapy in the second-line setting to full approval and expands the indication for Opdivo plus Yervoy into the first-line treatment [2] - The approval was based on the phase III CheckMate-8HW study, which showed that Opdivo plus Yervoy met the dual primary endpoints of progression-free survival compared to Opdivo monotherapy and chemotherapy [4][5] - Opdivo plus Yervoy demonstrated a 79% reduction in the risk of disease progression or death compared to chemotherapy in the first-line setting and a 38% reduction versus Opdivo monotherapy across all lines of therapy [5] - The approval was granted more than two months ahead of the target action date of June 23, 2025, with ongoing studies assessing various secondary endpoints, including overall survival [6] Market Performance - BMY shares have increased by 7.9% over the past year, contrasting with a 20% decline in the industry [3] Portfolio Expansion - The approval of Opdivo continues to enhance BMY's immuno-oncology portfolio, with expectations for sustained impact into the next decade [7] - BMY's growth portfolio, which includes drugs like Reblozyl, Breyanzi, Camzyos, and Opdualag, has stabilized revenue amid generic competition for legacy drugs [10] - The company has also recently acquired 2seventy bio, Inc. for $286 million, sharing profits and losses related to the development of Abecma in the U.S. [12]